血液科指南

订阅

MedSci主页 / 所有栏目 / 血液科指南

硫培非格司亭临床应用专家共识

2020-05-30 中国临床肿瘤学会抗肿瘤药物安全管理专家委员会 临床肿瘤学杂志.2020,25(5):461-165.

重组人粒细胞刺激因子

硫培非格司亭注射液( HHPG-19K) 是在非格司亭的基础上进行聚乙二醇修饰而成的长效重组人粒细胞刺激因子制剂。2018 年5 月硫培非格司亭获得国家药品监督管理局批准用于成年非髓性恶性肿瘤放化疗引

中文标题：

硫培非格司亭临床应用专家共识

发布机构：

中国临床肿瘤学会抗肿瘤药物安全管理专家委员会

发布日期：

2020-05-30

简要介绍：

硫培非格司亭注射液( HHPG-19K) 是在非格司亭的基础上进行聚乙二醇修饰而成的长效重组人粒细胞刺激因子制剂。2018 年5 月硫培非格司亭获得国家药品监督管理局批准用于成年非髓性恶性肿瘤放化疗引起的中性粒细胞减少伴感染患者。为了指导临床上规范化应用和患者管理，根据我国的临床研究结果，结合国内外权威学术机构的指南和目前国内硫培非格司亭应用现状，中国临床肿瘤学会( CSCO) 抗肿瘤药物治疗安全管理专家委员会组织多学科专家合作，认真讨论，反复修改，制定了本共识，以供临床医师参考。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=硫培非格司亭临床应用专家共识_马军.pdf)] GetToolGuiderByIdResponse(projectId=1, id=e0ee91c001926833, title=硫培非格司亭临床应用专家共识, enTitle=, guiderFrom=临床肿瘤学杂志.2020,25(5):461-165., authorId=0, author=, summary=硫培非格司亭注射液( HHPG-19K) 是在非格司亭的基础上进行聚乙二醇修饰而成的长效重组人粒细胞刺激因子制剂。2018 年5 月硫培非格司亭获得国家药品监督管理局批准用于成年非髓性恶性肿瘤放化疗引, cover=https://img.medsci.cn/2020626/1593185921149_2020535.jpg, journalId=0, articlesId=null, associationId=964, associationName=中国临床肿瘤学会抗肿瘤药物安全管理专家委员会, associationIntro=null, copyright=0, guiderPublishedTime=Sat May 30 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>硫培非格司亭注射液( HHPG-19K) 是在非格司亭的基础上进行聚乙二醇修饰而成的长效重组人粒细胞刺激因子制剂。2018 年5 月硫培非格司亭获得国家药品监督管理局批准用于成年非髓性恶性肿瘤放化疗引起的中性粒细胞减少伴感染患者。为了指导临床上规范化应用和患者管理，根据我国的临床研究结果，结合国内外权威学术机构的指南和目前国内硫培非格司亭应用现状，中国临床肿瘤学会( CSCO) 抗肿瘤药物治疗安全管理专家委员会组织多学科专家合作，认真讨论，反复修改，制定了本共识，以供临床医师参考。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=38874, tagName=重组人粒细胞刺激因子)], categoryList=[CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=38874, guiderKeyword=重组人粒细胞刺激因子, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7471, appHits=104, showAppHits=0, pcHits=1416, showPcHits=7366, likes=3, shares=8, comments=5, approvalStatus=1, publishedTime=Fri Jun 26 23:56:22 CST 2020, publishedTimeString=2020-05-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Fri Jun 26 23:38:46 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 18:45:05 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=硫培非格司亭临床应用专家共识_马军.pdf)])
硫培非格司亭临床应用专家共识_马军.pdf
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=923782, encodeId=e17a923e82e7, content=今天刚看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Feb 08 22:17:54 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912733, encodeId=23c3912e331a, content=中国临床肿瘤学会( CSCO) 抗肿瘤药物治疗安全管理专家委员会组织多学科专家合作，认真讨论，反复修改，制定了本共识，以供临床医师参考, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Thu Dec 31 20:41:19 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902608, encodeId=5ba8902608d3, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Thu Nov 26 21:22:26 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896441, encodeId=812f89644117, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3405327796, createdName=148c1ad7m20暂无昵称, createdTime=Tue Nov 03 00:00:15 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896440, encodeId=657e896440c3, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3405327796, createdName=148c1ad7m20暂无昵称, createdTime=Mon Nov 02 23:59:55 CST 2020, time=2020-11-02, status=1, ipAttribution=)]
    2021-02-08 12314969m72暂无昵称

    今天刚看

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=923782, encodeId=e17a923e82e7, content=今天刚看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Feb 08 22:17:54 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912733, encodeId=23c3912e331a, content=中国临床肿瘤学会( CSCO) 抗肿瘤药物治疗安全管理专家委员会组织多学科专家合作，认真讨论，反复修改，制定了本共识，以供临床医师参考, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Thu Dec 31 20:41:19 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902608, encodeId=5ba8902608d3, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Thu Nov 26 21:22:26 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896441, encodeId=812f89644117, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3405327796, createdName=148c1ad7m20暂无昵称, createdTime=Tue Nov 03 00:00:15 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896440, encodeId=657e896440c3, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3405327796, createdName=148c1ad7m20暂无昵称, createdTime=Mon Nov 02 23:59:55 CST 2020, time=2020-11-02, status=1, ipAttribution=)]
    2020-12-31 oo902

    中国临床肿瘤学会( CSCO) 抗肿瘤药物治疗安全管理专家委员会组织多学科专家合作，认真讨论，反复修改，制定了本共识，以供临床医师参考

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=923782, encodeId=e17a923e82e7, content=今天刚看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Feb 08 22:17:54 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912733, encodeId=23c3912e331a, content=中国临床肿瘤学会( CSCO) 抗肿瘤药物治疗安全管理专家委员会组织多学科专家合作，认真讨论，反复修改，制定了本共识，以供临床医师参考, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Thu Dec 31 20:41:19 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902608, encodeId=5ba8902608d3, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Thu Nov 26 21:22:26 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896441, encodeId=812f89644117, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3405327796, createdName=148c1ad7m20暂无昵称, createdTime=Tue Nov 03 00:00:15 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896440, encodeId=657e896440c3, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3405327796, createdName=148c1ad7m20暂无昵称, createdTime=Mon Nov 02 23:59:55 CST 2020, time=2020-11-02, status=1, ipAttribution=)]
    2020-11-26 carolinewy

    感谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=923782, encodeId=e17a923e82e7, content=今天刚看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Feb 08 22:17:54 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912733, encodeId=23c3912e331a, content=中国临床肿瘤学会( CSCO) 抗肿瘤药物治疗安全管理专家委员会组织多学科专家合作，认真讨论，反复修改，制定了本共识，以供临床医师参考, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Thu Dec 31 20:41:19 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902608, encodeId=5ba8902608d3, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Thu Nov 26 21:22:26 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896441, encodeId=812f89644117, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3405327796, createdName=148c1ad7m20暂无昵称, createdTime=Tue Nov 03 00:00:15 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896440, encodeId=657e896440c3, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3405327796, createdName=148c1ad7m20暂无昵称, createdTime=Mon Nov 02 23:59:55 CST 2020, time=2020-11-02, status=1, ipAttribution=)]
    2020-11-03 148c1ad7m20暂无昵称

    感谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=923782, encodeId=e17a923e82e7, content=今天刚看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72fa2381620, createdName=12314969m72暂无昵称, createdTime=Mon Feb 08 22:17:54 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=912733, encodeId=23c3912e331a, content=中国临床肿瘤学会( CSCO) 抗肿瘤药物治疗安全管理专家委员会组织多学科专家合作，认真讨论，反复修改，制定了本共识，以供临床医师参考, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Thu Dec 31 20:41:19 CST 2020, time=2020-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902608, encodeId=5ba8902608d3, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Thu Nov 26 21:22:26 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896441, encodeId=812f89644117, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3405327796, createdName=148c1ad7m20暂无昵称, createdTime=Tue Nov 03 00:00:15 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896440, encodeId=657e896440c3, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3405327796, createdName=148c1ad7m20暂无昵称, createdTime=Mon Nov 02 23:59:55 CST 2020, time=2020-11-02, status=1, ipAttribution=)]
    2020-11-02 148c1ad7m20暂无昵称

    感谢分享

    0

相关指南

2016 聚乙二醇化重组人粒细胞刺激因子（PEG-rhG-CSF）临床应用中国专家共识

中国临床肿瘤学会(CSCO,Chinese Society of Clinical Oncology) · 2016-04-30

拓展阅读

2016 聚乙二醇化重组人粒细胞刺激因子（PEG-rhG-CSF）临床应用中国专家共识

中国临床肿瘤学会(CSCO,Chinese Society of Clinical Oncology) · 2016-04-30